New gene editing technologies are enabling exploration of previously intractable features of genetic risk for drug addiction. A recent study using this technology reveals new insights into how a mutation linked to tobacco dependence influences the addictive properties of nicotine.
Cigarette smoking is one the leading preventable causes of diseases worldwide [1, 2] . The development and persistence of cigarette smoking is believed to stem from the actions of nicotine [3] , which can potently modulate brain activity by acting at neuronal nicotinic acetylcholine receptors (nAChRs). These nAChRs are distributed throughout the brain, including neural circuits known to control the rewarding properties of nicotine and other drugs of abuse [4] . Just over 10 years ago, a single nucleotide polymorphism (SNP) in the CHRNA5 gene (rs16969968), which encodes the a5 nAChR subunit (termed a5* nAChRs), was identified as a major risk factor for nicotine dependence [5, 6] , and many of the health problems associated with the tobacco habit [7] ; a surprising result given the small fraction of the total number of nAChRs in the brain that contain the a5 subunit.
The a5* rs16969968 SNP is thought to reduce the function of the nAChRs that incorporate the mutant subunit [8, 9] . Studies investigating how this loss of function may influence brain responses to nicotine have given key insights into the mechanisms of nicotine dependence. Specifically, transgenic mice engineered to completely lack expression of a5 nAChR subunits (Chrna5 -/mice) are less sensitive to aversive qualities of nicotine that normally limit intake [10] . This 'brake' on nicotine consumption is relayed by neural connections between the medial habenula and the interpeduncular nucleus, which are enriched in a5* nAChRs. Heavy smoking in carriers of the rs16969968 SNP may therefore reflect diminished capacity of a5* nAChRs to stimulate the medial habenulainterpeduncular nucleus pathway and thereby curb nicotine consumption [10, 11] .
An important caveat to these previous findings is that the Chrna5 -/mice used in these studies completely lack a5 nAChRs, which contrasts with humans who carry the rs16969968 (or other) SNP and express a5* nAChRs with altered function. Hence, it is possible that complete genetic ablation of a5 subunits in Chrna5 -/mice has different outcomes than mutations that more subtly alter a5* nAChRs function. Consequently, animal models that more faithfully capture the influence of the rs16969968 risk allele in the brains of smokers are needed. As they report in this issue of Current Biology, Forget et al. [12] capitalized on precision gene editing technologies to generate a transgenic rat that expresses the rs16969968 SNP in the Chrna5 gene and show that this manipulation markedly alters addiction-relevant actions of nicotine in the mutant animals ( Figure 1 ).
First, Forget et al. [12] used zincfinger nucleases to introduce the rs16969968 SNP into the Chrna5 gene of rats. Using this gene editing approach, they observed little evidence of 'off-target' genetic effects, suggesting that the modification was efficacious and accurate. For comparison, they used the same approach to completely ablate the Chrna5 gene in rats, similar to the Chrna5 -/mice described above. As expected, a5 subunits were undetectable in the brains of the rats in which the Chrna5 gene was entirely ablated, although the total amounts of nAChRs detected across multiple brain regions were generally similar between the knockout and wild-type rats. Rats expressing the rs16969968 SNP showed levels of a5 subunits, and also total amounts of nAChRs, that were indistinguishable from wild-type rats, importantly demonstrating that the addiction-relevant SNP does not markedly alter the expression of a5* nAChRs in the brain, but instead is likely to impact the function of these nAChRs.
Next, Forget et al. [12] examined the motivational properties of nicotine in the mutant rats. In rodents, the intravenous self-administration procedure is often used to quantify the reinforcing properties of drugs of abuse. In this procedure, rats are trained to emit a response, typically to press a lever, to earn an intravenous infusion of nicotine. Delivery of the nicotine infusion is usually paired with the presentation of a cue, such as a light that is activated each time a nicotine reward is delivered, that gradually comes to predict availability of the drug. Once reliable nicotine-taking behavior is established, experimenters can alter the dosage of nicotine that is available for consumption or the numbers of lever presses that are required to earn an infusion. In this manner, sensitivity to the dose of nicotine, and the willingness of the animals to work for nicotine infusions, can be assessed. The authors found that rats in which the Chrna5 gene was completely ablated did not acquire nicotine self-administration behavior. By contrast, they observed no differences in the rates of acquisition in the SNPexpressing mutant rats compared with wild-type rats. However, major differences in nicotine-taking behavior emerged between the SNP-expressing and wild-type rats as the dose of nicotine was increased. Specifically, the wild-type rats scaled back their responding for the drug as the dose increased to maintain relatively constant levels of nicotine independent of the dose available. By contrast, the mutant rats did not scale back their responding as the dose increased, resulting in ever greater levels of nicotine intake.
Next, intravenous self-administration determined how motivated the rats were to obtain nicotine, as indexed by the number of lever presses that they were willing to invest in order to earn an infusion. They found that the mutant rats were willing to work much harder than the wild-type animals for nicotine when higher doses of the drug were available. These findings are strikingly similar to the patterns of responding for nicotine previously reported in Chrna5 -/mice [10] , and suggest that the rs16969968 SNP results in diminished function of a5* nAChRs in those who carry the risk allele, which increases the amounts of nicotine that are consumed and also the motivation to seek out the drug.
Stimulatory effects of nicotine on dopamine neurons in the ventral tegmental area are thought to play a critical role in the motivational properties of the drug that support the development and maintenance of smoking: a5* nAChRs are expressed in this brain region and may contribute to the stimulatory effects of nicotine on dopamine neurons. Forget et al. [12] therefore determined whether the actions of nicotine on ventral tegmental area neurons were altered in the a5 subunit mutant rats. They found that the same nicotine dose used to support the acquisition of nicotine selfadministration behavior increased the activity of ventral tegmental area neurons to a similar degree in the SNPexpressing and wild-type rats. This suggests that the increased nicotinetaking behavior observed in the SNPexpressing rats is unlikely to be explained by altered responsiveness of ventral tegmental area neurons to nicotine and that other addiction-relevant brain circuits are likely to play a role. Strikingly, however, the stimulatory effects of nicotine on ventral tegmental area neurons were almost completely abolished in the knockout rats in which Chrna5 was ablated. This likely explains why these knockout rats failed to acquire nicotine self-administration behavior. More broadly, these findings demonstrate just how different the When laboratory rodents, and presumably human smokers, consume nicotine the drug activates pentameric nAChRs that are comprised of a and b nAChR subunits. nAChRs that incorporate a5 subunits are enriched in the MHb-interpeduncular nucleus circuit and regulate the stimulatory effects of nicotine on this circuit. Activation of the MHb-interpeduncular nucleus circuit triggers a signal that results in cessation of nicotine intake. Therefore, incorporation of a5 subunits that contain the rs16969968 SNP into nAChRs can result in diminished sensitivity of the MHb-interpeduncular nucleus circuit to the stimulatory actions of nicotine, greater nicotine intake and, potentially, increased vulnerability to relapse during periods of abstinence.
outcome can be when a gene is knockout versus relative to the effects when the same gene contains diseaserelevant mutations, and highlights the immense power of emerging genome editing technologies to better understand the mechanisms of genetic risk for addiction and other psychiatric disorders.
Most cigarette smokers express a desire to quit tobacco use and will frequently attempt to abstain, but the vast majority quickly relapse to continued use [13] . Relapse can be precipitated by re-exposure to cigarette smoke or by encountering stimuli that predict nicotine availability, such as the sight or smell of a lit cigarette. Maintaining long-term abstinence is the major hurdle to successfully quitting the cigarette habit. Hence, understand in factors that influence vulnerability to relapse is critical for developing improved smoking cessation therapeutics. To investigate if the a5 SNP modulates relapse-like behavior in rats, Forget et al. [12] discontinued the delivery of nicotine infusions, and activation of the associated visual cue, in response to nicotine-seeking lever presses. This uncoupling of lever pressing behavior from nicotine delivery normally results in a gradual decrease in responding, a process termed extinction. Extinguished drug-seeking behavior can be restored by 'priming' rats with an injection of nicotine, presenting to them the nicotinepaired cue light, or both. This 'reinstatement' of lever pressing behavior is considered a metric of relapse. After being exposed to nicotine, or the visual cue associated with nicotine delivery, the SNP-expressing rats exhibited far stronger reinstatement of nicotineseeking lever pressing responses than the wild-type rats. This finding raises the intriguing possibility that the rs16969968 SNP influences risk of relapse in abstinent smokers.
Finally, Forget et al. [12] sought to identify brain circuits through which the rs16969968 SNP may influence relapse-like behavior in rats. By quantifying markers of neural activation after the reinstatement test, they found increased recruitment of the lateral hypothalamus, lateral habenula, and posterior ventral tegmental area in the SNP-expressing rats compared with wild-type rats. These sites have all been previously implicated in relapserelated behaviors. Intriguingly, they also found a negative correlation between recruitment of the interpeduncular nucleus and the degree of reinstatement, and generally less activation in the interpeduncular nucleus of SNPexpressing rats. This is the same brain region that was shown to be less sensitive to nicotine in the Chrna5 -/mice and that controls nicotine selfadministration behavior. Hence, this finding may reflect a previously unappreciated role for the interpeduncular nucleus in preventing relapse behaviors.
The quest to understand how heritable elements influence risk of neuropsychiatric disorders often begins by inferring the function of such genetic elements based on observations from animals in which such elements are knocked out or overexpressed. As fundamental as these studies are, it is important to keep in mind that the systems-wide impact of lacking or overexpressing a gene is likely to be different from the effects of a diseaseassociated mutation that has more subtle effects in the function of a protein coded by that gene. This potential disparity, when considered in light of the frequent failures of attempts to translate findings generated from mice expressing null mutations in genes to the clinic, has considerable implications for understanding the pathophysiology of brain disorders and for drug development. Modifying genes more specifically to express mutations linked to disease is likely to more faithfully recapitulate the human condition, and may therefore possess greater translational utility. Here, by employing such gene editing approaches, the present studies shed important new light on the functional impact of the rs16969968 SNP in CHRNA5 that is known to influence vulnerability to nicotine addiction and relapse in human smokers.
